ProCE Banner Activity

Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs

Podcast Episodes
Listen to Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, as they answer audience questions from a live webinar about how to best use the plethora of active agents and regimens now available for patients with advanced multiple myeloma.

Released: August 24, 2021

Expiration: August 23, 2022

No longer available for credit.

Share

Faculty

Paul G. Richardson

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Nina Shah

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Peter Michael Voorhees

Peter Michael Voorhees, MD

Assistant Professor of Medicine
Department of Hematology/Oncology
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

GlaxoSmithKline

Karyopharm

Oncopeptides

Sanofi Genzyme

Program Director Disclosure

Program Director

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb/Celgene, Karyopharm, Oncopeptides, and Takeda and consulting fees from AstraZeneca, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio, and Takeda.

Faculty Disclosure

Primary Author

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Nina Shah, MD, has disclosed that she has received funds for research from Bluebird Bio, Celgene/Bristol-Myers Squibb, Janssen, Nektar, Poseida, Precision Biosciences, Sutro Biopharma, and TeneoBio and consulting fees for an advisory role from Amgen, CareDx, CSL Behring, GlaxoSmithKline, Indapta Therapeutics, Karyopharm, Kite, Oncopeptides, and Sanofi.

Peter Michael Voorhees, MD

Assistant Professor of Medicine
Department of Hematology/Oncology
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Peter M. Voorhees, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Novartis, Oncopeptides, and SecuraBio and has served on the advisory board for AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Pfizer, and Sanofi.